BE900925A - Nouvelle forme cristalline alpha, anhydre et stable, du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci. - Google Patents

Nouvelle forme cristalline alpha, anhydre et stable, du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci.

Info

Publication number
BE900925A
BE900925A BE0/213911A BE213911A BE900925A BE 900925 A BE900925 A BE 900925A BE 0/213911 A BE0/213911 A BE 0/213911A BE 213911 A BE213911 A BE 213911A BE 900925 A BE900925 A BE 900925A
Authority
BE
Belgium
Prior art keywords
degrees
anhydrous
prazosin hydrochloride
crystalline form
micro
Prior art date
Application number
BE0/213911A
Other languages
English (en)
French (fr)
Inventor
S O E Lindholm
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Publication of BE900925A publication Critical patent/BE900925A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BE0/213911A 1984-06-25 1984-10-29 Nouvelle forme cristalline alpha, anhydre et stable, du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci. BE900925A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI842544A FI79107C (fi) 1984-06-25 1984-06-25 Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.

Publications (1)

Publication Number Publication Date
BE900925A true BE900925A (fr) 1985-02-15

Family

ID=8519293

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/213911A BE900925A (fr) 1984-06-25 1984-10-29 Nouvelle forme cristalline alpha, anhydre et stable, du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci.

Country Status (17)

Country Link
US (2) US4739055A (enExample)
JP (1) JPS6115881A (enExample)
AT (1) AT389117B (enExample)
AU (1) AU566814B2 (enExample)
BE (1) BE900925A (enExample)
CH (1) CH661045A5 (enExample)
DE (1) DE3429415A1 (enExample)
FI (1) FI79107C (enExample)
FR (1) FR2567124B1 (enExample)
GB (1) GB2160861B (enExample)
IL (1) IL73267A (enExample)
IT (1) IT1224142B (enExample)
LU (1) LU85616A1 (enExample)
NL (1) NL8403250A (enExample)
NZ (1) NZ209962A (enExample)
PT (1) PT79411B (enExample)
ZA (1) ZA85910B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816455A (en) * 1986-03-21 1989-03-28 Heumann Pharma Gmbh & Co. Crystalline, anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxy-quinazoline hydrochloride and a process for its preparation

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2756846B2 (ja) * 1989-12-28 1998-05-25 住化ファインケム株式会社 無水のε型結晶体２―〔４―（２―フロイル）ピペラジン―１―イル〕―４―アミノ―６，７―ジメトキシキナゾリン塩酸塩及びその製造方法
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
DE50209483D1 (de) * 2001-02-24 2007-03-29 Boehringer Ingelheim Pharma Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
NZ600394A (en) * 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0917675A2 (pt) * 2008-08-15 2015-12-01 Boehringer Ingelheim Int compostos orgânicos para cura de ferida
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
PH12012502162A1 (en) 2010-05-05 2013-02-04 Boehringer Ingelheim Int Combination therapy
EP2585101A1 (en) 2010-06-24 2013-05-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2969375A (en) * 1961-01-24 Certification of correction
DE156532C (enExample) *
BE427505A (enExample) * 1937-05-25
GB1156973A (en) * 1965-07-06 1969-07-02 Quinazoline Derivatives
US3433788A (en) * 1966-04-27 1969-03-18 Union Carbide Corp Process for recovery of amines from aqueous solutions by solvent treatment and distillation
US3421983A (en) * 1967-03-07 1969-01-14 Lummus Co Azeotropic distillation of aqueous toluene diamine
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3743672A (en) * 1970-05-27 1973-07-03 Halcon International Inc Separation of water in alkylene glycol mono and diester purification by azeotropic distillation
GB1308718A (en) * 1970-07-01 1973-03-07 Sir Soc Italiana Resine Spa Method of separating vinyl acetate from liquid mixtures
IT956765B (it) * 1972-06-22 1973-10-10 Montedison Spa Procedimento per la purificazione di 1 3 diossolano
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4001237A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
FI67699C (fi) * 1979-01-31 1985-05-10 Orion Yhtymae Oy Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan
FI64367C (fi) * 1980-02-26 1986-08-05 Orion Yhtymae Oy Foerfarande foer framstaellning av alfa-form av prazosinhydroklorid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816455A (en) * 1986-03-21 1989-03-28 Heumann Pharma Gmbh & Co. Crystalline, anhydrous sigma-form of 2-(4-(2-furoyl)-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxy-quinazoline hydrochloride and a process for its preparation

Also Published As

Publication number Publication date
NZ209962A (en) 1987-06-30
GB2160861A (en) 1986-01-02
IL73267A (en) 1988-06-30
GB8424999D0 (en) 1984-11-07
FI79107B (fi) 1989-07-31
US4873330A (en) 1989-10-10
JPS6115881A (ja) 1986-01-23
IL73267A0 (en) 1985-01-31
FI842544L (fi) 1985-12-26
IT1224142B (it) 1990-09-26
AT389117B (de) 1989-10-25
NL8403250A (nl) 1986-01-16
AU3451084A (en) 1986-01-02
FI842544A0 (fi) 1984-06-25
GB2160861B (en) 1987-11-18
FR2567124B1 (fr) 1990-09-21
LU85616A1 (fr) 1985-06-04
FI79107C (fi) 1989-11-10
PT79411B (en) 1986-09-15
FR2567124A1 (fr) 1986-01-10
IT8423292A0 (it) 1984-10-24
DE3429415A1 (de) 1986-01-02
ATA344184A (de) 1989-03-15
ZA85910B (en) 1985-09-25
DE3429415C2 (enExample) 1990-05-03
US4739055A (en) 1988-04-19
PT79411A (en) 1984-11-01
JPH0481993B2 (enExample) 1992-12-25
AU566814B2 (en) 1987-10-29
CH661045A5 (de) 1987-06-30

Similar Documents

Publication Publication Date Title
BE900925A (fr) Nouvelle forme cristalline alpha, anhydre et stable, du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci.
KR850006391A (ko) 벤조치아졸 및 벤조치오펜 유도체의 제조방법
HUT59376A (en) Process for producing r(+)-n-propargyl-1-aminoindane and pharmaceutical compositions comprising such compound
RU92016217A (ru) Двойные ингибиторы no синтазы и циклооксигеназы, способ их получения и фармацевтическая композиция на их основе
ES8800900A1 (es) Procedimiento para preparar derivados de amidoindol y amidoindazol
FR2669635B1 (fr) Procede de fabrication d'hydroxymethylfurfural (hmf) du purete elevee.
DK0532515T3 (da) Fremstilling af substituerede piperidiner
EA200100533A1 (ru) Производные эритромицина, способ их получения и их применение в качестве лекарственных средств
DE69207429D1 (de) Verfahren zur herstellung von substituierten piperidinen
MA19948A1 (fr) Procede de preparation de derives de la piperidine-dione protecteur du myocarde presentant une activite antiarithmique
YU182581A (en) Process for preparing new 5,10-dihydro-11h-dibenzo-(b,e)(1,4)diazepine-11-ones substituted in position 5
ES8706598A1 (es) Un procedimiento para preparar nuevos derivados de aminocetona
MD970135A (en) Arylthiocompound as an antibacterial and antiviral remedy
IT1147045B (it) Lamine di lega di alluminio per catodi di condensatori elettrolitici
RU2002124524A (ru) Производные n-деацетилтиоколхицина и содержащие их фармацевтические композиции
SE8803765D0 (sv) Nya isopolypeptider samt foerfarande foer framstaellning av desamma
McCord et al. Diastereomers of 2-amino-3-methylaminobutyric acid, aza analogs of isoleucine
AU568101B2 (en) Pharmaceutical benzazepines and benzdiazepines
SE7906681L (sv) Ftalazonderivat
SE8801798L (sv) Chemical intermediates and process
DK104388D0 (da) Hidtil ukendte 2-(2,3-dihydro-2-oxo-3-benzofuranyl)-eddikesyrederivater, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem
ES467100A1 (es) Un procedimiento para la obtencion de (+,-)-cis-alfa-(3- (2,6-dimetil-1-piperidinil) propil)alfa-fenil-2-piridin-me- tanol.
JPS55164671A (en) Azetidine derivative and its preparation
GB1456946A (en) 6-phenyl-4h-imidazo-1,2-a-1,4-benzodiazepines
ATE33837T1 (de) Azolylmethylcycloacetale, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: ORION-YHTYMA OY FERMION

Effective date: 19951031